Watch out, Eli Lilly and Novo Nordisk. Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs ...
A $93 billion plunge in Novo Nordisk A/S shares has provided the latest blow to Europe’s largest listed companies, which have ...
Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...
Volkswagen on Friday announced sweeping changes to its German operations, including more than 35,000 future job cuts and ...
Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...
The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...
Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback